Ockham Research Staff @ October 16, 2008 # No Comment Yet
NBTY, formerly known as Nature’s Bounty, (Symbol: NTY) reported healthy sales gains for the quarter just ended. However, the stock took a dive after those quarterly results failed to live up to estimates. So, NBTY looks to be Undervalued, but we remain cuatious in this investing environment because overall market action is still decidedly negative.
More on: Ple{NTY} of Reasons to Take Your Vitamins
Ockham Research Staff @ October 14, 2008 # No Comment Yet
Johnson & Johnson reported better than expected performance in the quarter just ended. Sales growth was solid and management did a great job managing the company through a difficult environment. If you are looking to pull back into a more defensive stock that also has some upside potential, take a look at JNJ.
More on: Johnson & Johnson Staying Healthy
Ockham Research Staff @ October 6, 2008 # No Comment Yet
It is not easy to be bullish right now, but sometimes being a contrarian is tough to stomach. However, it has been shown to work in the past if you have the discipline to adhere to the strategy.
More on: Adhering to a Value Investing Strategy
Ockham Research Staff @ September 30, 2008 # No Comment Yet
An overview of the changes to our newsletter and the announcement that coverage for all 100 equities covered on our Ockham Research web site will be avialable to the public for free. Please visit www.ockhamresearch.com to view these research reports.
More on: The EIG Newsletter Gets a Makeover
Ockham Research Staff @ September 22, 2008 # 2 Comments
in this article we are highlighting a great mid-cap company in the Healthcare IT market. QSII has grown by leaps and bounds as the electrionic medical records (EMR) market has expanded greatly. The trend shows little signs of slowing and this stock may represent a good buy even though it is up more than 35% in the last 6 weeks.
More on: Quality Systems, Inc. is Poised to Continue Growth
Ockham Research Staff @ July 16, 2008 # No Comment Yet
ABT Labs blew past earnings expectations as profit jumped 34%. We are reiterating our Buy rating as fundamentals have greatly improved and in a tough environment. This is a sign of exceptional management which is something we are always eager to find.
More on: Abbott Labs Delivers Above Expectations
Ockham Research Staff @ May 20, 2008 # No Comment Yet
Medtronic (MDT) reported its fiscal fourth quarter (ended April 25) results prior to trading Tuesday morning. The medical device company reported flat net income from results a year ago that were aided by a tax gain. However, revenues rose by more than 18%, thanks in large part to the introduction of the Endeavor drug-dispensing stent. […]
More on: Medtronic Beats Estimates
admin @ March 31, 2008 # No Comment Yet
It was a rough Monday morning for stock owners of Merck & Co. ( MRK) and Schering-Plough Corp. ( SGP) as a panel of cardiologists recommended that Doctors sharply reduce their prescribing of the companies’ jointly marketed cholesterol drugs Vytorin and Zetia. The cardiologists based their claim in the results […]
More on: Monday brings Heartburn for Schering-Plough
admin @ February 4, 2008 # No Comment Yet
It was a relatively slow day for news coming out of the markets, and there is about as much coverage of Super Bowl commercials as anything else. Perhaps Wall Street is a little slow in recovering from a night of partying after the New York Giants pulled off the stunning upset […]
More on: Take a Close Look at Amgen